As the 2024 presidential election evolves, ADVI experts are closely monitoring the healthcare issues with the potential for significant policy changes, including drug pricing regulations, healthcare reform, and shifts in regulatory priorities. Policies like the Inflation Reduction Act (IRA), are poised to have significant implications for many life sciences companies, impacting drug reimbursement, regulatory compliance obligations, market access dynamics.

Below are resources and insights with up-to-date information on the healthcare issues that may impact you the most leading up to and following the 2024 presidential election. ADVI experts will continue to monitor this evolving healthcare landscape to help you effectively adapt your strategies to navigate potential market volatility, regulatory uncertainties, and changes in consumer behavior effectively.

Get In Touch